Avalyn Pharma INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
NASDAQ
Avalyn Pharma announced second quarter 2026 financial results, highlighting the completion of enrollment for its MIST Phase 2b trial of AP01 and a cash runway projected into 2029.
NASDAQ
Avalyn Pharma Inc. has amended its sublease agreement to expand its office space in Boston, Massachusetts, increasing its rentable square footage and future lease payments.